725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

• DOI: 10.1016/j.annonc.2021.08.1168
• Publication Date: 2021-09-21T19:00:18Z
• Authors: S. Banerjee; R. Grochot; R. Shinde; J. Lima; M. Krebs; R. Rahman; M. Little; N. Tunariu; A. Curcean; H. Badham; M. Mahmud; A. Turner; M. Parmar; C. Yap; A. Minchom; J. Lopez; J. de Bono; U. Banerji
• Keywords: Pharmacodynamics; Combination therapy